Hikma Pharmaceuticals PLC

LSE HIK.L

Hikma Pharmaceuticals PLC Cash and Short-Term Investments for the year ending December 31, 2023: USD 229.00 M

Hikma Pharmaceuticals PLC Cash and Short-Term Investments is USD 229.00 M for the year ending December 31, 2023, a -21.58% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Hikma Pharmaceuticals PLC Cash and Short-Term Investments for the year ending December 31, 2022 was USD 292.00 M, a -35.11% change year over year.
Hikma Pharmaceuticals PLC Cash and Short-Term Investments for the year ending December 31, 2021 was USD 450.00 M, a 29.68% change year over year.
Hikma Pharmaceuticals PLC Cash and Short-Term Investments for the year ending December 31, 2020 was USD 347.00 M, a -25.38% change year over year.
Hikma Pharmaceuticals PLC Cash and Short-Term Investments for the year ending December 31, 2019 was USD 465.00 M, a 56.57% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

LSE: HIK.L

Hikma Pharmaceuticals PLC

CEO	Mr. Riad Ali Mishlawi
IPO Date	Nov. 1, 2005
Location	United Kingdom
Headquarters	1 New Burlington Place
Employees	9,100
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Consumer Packaged Goods Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Key trends

Past 5 years